Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
about
Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Uterine sarcoma - current perspectives.Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.Current and future therapeutic approaches for osteosarcoma.Leiomyosarcoma of the Inferior Vena Cava in an HIV-Positive Adult Patient: A Case Report and Review of the Literature.Biology of Bone Sarcomas and New Therapeutic Developments.Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.Current status of immunotherapy for sarcomas.Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.Advances in the Treatment of Pediatric Bone Sarcomas.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".A review of soft-tissue sarcomas: translation of biological advances into treatment measures.Immunotherapies: Exploiting the Immune System for Cancer Treatment.Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcomaResponse to PD1 inhibition in conventional chondrosarcoma
P2860
Q33276468-72C20492-B114-4F18-8A7B-C68879150D41Q36389964-532B8D13-231D-4D61-9434-0A550BE3261DQ41634399-3F3938C2-6A07-4527-B2B7-EF76EA1B643BQ46265366-D973CF10-94E0-4AA7-B67D-6CB3E11BB004Q47096040-CDA699A8-B6E5-49AC-9AAD-A2E7CD26A56EQ47132242-D9A72498-F175-4AA2-B43E-F84DCDD0F0B4Q47199914-3C889A3D-3574-4DCF-92B8-97499680F93BQ47360357-67E94C52-94A3-4146-A230-E82705E5D10AQ47591592-A23E2D7D-B833-4E13-AEBA-730A6617E270Q48120956-9D78D592-96FB-4A11-AB24-02E02ED1A914Q49364445-98AC520F-58CD-46B9-975C-DF04252C6A16Q49557938-DAFDE737-92E4-473A-9E19-BC923E5DC97CQ49859661-8714C625-3FBE-47F5-AAD9-FBC72D076AF1Q50324271-BA666622-3A2A-4E03-991D-46D31A972E17Q50969326-2207721E-C7AF-41D7-96AF-ABC9950F0262Q52671439-D96D19AD-6434-4D82-A241-F4E754B38B06Q52682430-95810644-C585-4754-96D7-5650D3546A71Q54123848-6B863181-B20A-4464-BD7D-F0758025E1CBQ55265062-C03F8A0B-576D-4C97-9EF1-0EFBB3ACE23DQ55362851-5010F3D3-9448-4D46-86EE-C7DE3C67871FQ56887181-56C1EF62-4772-4AE7-8ED1-57A340A99D0CQ58698493-3FF860D5-E1E6-47C1-98E5-35A6473A2267
P2860
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@en
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@nl
type
label
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@en
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@nl
prefLabel
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@en
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.
@nl
P2093
P2860
P1476
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
@en
P2093
A Karambelkar
A Rapkiewicz
P2860
P2888
P356
10.1186/S13569-016-0064-0
P577
2016-12-30T00:00:00Z
P6179
1039948120